{"id":2071,"date":"2023-04-05T13:07:04","date_gmt":"2023-04-05T13:07:04","guid":{"rendered":"https:\/\/www.cic.vc\/?p=2071"},"modified":"2024-04-16T12:12:00","modified_gmt":"2024-04-16T12:12:00","slug":"bicycle-therapeutics-reports-first-quarter-2023-financial-results-and-provides-corporate-update","status":"publish","type":"post","link":"https:\/\/www.cic.vc\/bicycle-therapeutics-reports-first-quarter-2023-financial-results-and-provides-corporate-update\/","title":{"rendered":"Bicycle Therapeutics reports first quarter 2023 financial results and provides corporate update"},"content":{"rendered":"<p><a href=\"https:\/\/www.bicycletherapeutics.com\/\" target=\"_blank\" rel=\"noopener\">Bicycle Therapeutics<\/a> plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle\u00ae) technology, today reported financial results for the first quarter ended March 31, 2023 and provided recent corporate updates.<\/p>\n<p>\u201cThe beginning of 2023 has been impactful for Bicycle and our platform,\u201d said Kevin Lee, Ph.D., Chief Executive Officer of Bicycle Therapeutics. \u201cWe reported encouraging Phase I dose escalation results from BT8009 that showed anti-tumor activity in heavily pre-treated urothelial, lung and breast cancer patients and a median duration of response estimated to be 14 months in the 5 mg\/m2 cohort of patients with urothelial cancer. We look forward to providing further updates on BT8009 as well as on our other clinical-stage programs later this year.\u201d<\/p>\n<p>\u201cIn addition, we entered into multiple research and development collaborations with organizations at the forefront of the development of radiopharmaceuticals to develop Bicycle\u00ae radio-conjugates (BRCs),\u201d added Dr. Lee. \u201cThese collaborations provide further validation of our platform and enable us to advance a broad pipeline of partnered and wholly owned BRCs. This represents the third pillar of our oncology strategy beyond our Bicycle toxin conjugate (BTC\u2122) and Bicycle tumor-targeted immune cell agonist\u00ae (Bicycle TICA\u2122) programs. We are pleased with the progress we have made advancing our entire pipeline and expanding the potential applications of the Bicycle platform.\u201d<\/p>\n<p><strong>First Quarter 2023 and Recent Highlights<\/strong><\/p>\n<ul>\n<li><strong>Announced Multiple Strategic Collaborations for Developing BRCs for Potential Oncology Targets<\/strong>\n<ul>\n<li><strong>Strategic Collaboration with Novartis.<\/strong> In March 2023, Bicycle announced a strategic collaboration with Novartis to collaborate on the discovery, development and commercialization of BRCs for multiple undisclosed oncology targets. Bicycle will utilize its proprietary phage platform to discover Bicycles to be developed into BRCs. Novartis will be responsible for and fund further development, manufacture and commercialization of the BRCs. Bicycle received a $50 million upfront payment in April 2023 and is eligible for development and commercial-based milestone payments totaling up to $1.7 billion. Bicycle will also be eligible to receive tiered royalties on Bicycle-based medicines commercialized by Novartis.<\/li>\n<li><strong>Collaboration with the German Cancer Research Center.<\/strong> In May 2023, Bicycle announced a collaboration with the German Cancer Research Center (DKFZ) to develop and discover BRCs for potential oncology targets. Bicycle and DKFZ have been collaborating on preclinical development of tumor targeting BRCs which have shown encouraging tumor uptake in preclinical studies. With this new alliance, the relationship has expanded to include a more continuous and purpose-driven commitment towards advancing wholly owned BRCs. Bicycle intends to commence initial testing of its wholly owned BRCs in patients by the end of 2024.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Presented Completed BT8009 Phase I Dose Escalation Results from Ongoing Phase I\/II Study of BT8009 at the 2023 American Society for Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium.<\/strong> In February 2023, Bicycle presented monotherapy Phase I dose escalation results of the ongoing Phase I\/II trial of BT8009, a novel BTC\u2122 targeting Nectin-4, at the ASCO GU Cancers Symposium. BT8009 demonstrated anti-tumor activity in heavily pre-treated urothelial, lung and breast cancer patients with signs of differentiation compared to antibody-based approaches. Bicycle announced that it dosed its first patient in the Phase II expansion portion of the trial and established recommended Phase II doses of 5 mg\/m2 weekly and 7.5 mg\/m2 administered two-weeks on, one-week off over a 21-day cycle in November 2022. Enrollment in the clinical trial as well as discussions with the U.S. Food and Drug Administration (FDA) remain ongoing. The company expects to provide clinical and regulatory updates on BT8009 in 2023.<\/li>\n<li><strong>BT8009 Granted Fast Track Designation (FTD) by the FDA.<\/strong> In January 2023, Bicycle announced that the FDA granted BT8009 FTD as a monotherapy for the treatment of adult patients with previously treated locally advanced or metastatic urothelial cancer.<\/li>\n<li><strong>Enhanced Leadership Team with Key Appointments\u00a0<\/strong>\n<ul>\n<li>Bicycle appointed Santiago Arroyo M.D., Ph.D., as Chief Development Officer in March 2023. Dr. Arroyo brings to Bicycle over 20 years of biopharmaceutical industry experience, leading the clinical development of therapeutics across multiple disease areas. Dr. Arroyo will be responsible for overseeing all aspects of the pipeline as it continues to expand and advance and as Bicycle prepares to transition into late-stage clinical development.<\/li>\n<li>Bicycle promoted Jennifer Perry, Pharm.D., to Senior Vice President, Commercial. In this role, she will be responsible for establishing and growing the commercial organization<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><strong>Financial Results<\/strong><\/p>\n<ul>\n<li>Cash and cash equivalents were $293.8 million as of March 31, 2023, compared to $339.2 million as of December 31, 2022. The decrease in cash is primarily due to cash used in operating activities. Cash at March 31, 2023 does not include the upfront payment from Novartis.<\/li>\n<li>Research and development expenses were $32.2 million for the three months ended March 31, 2023, compared to $14.3 million for the three months ended March 31, 2022. The increase in expense of $17.9 million was primarily due to increased clinical program expenses for BT5528 and BT8009, Bicycle TICA program development expenses, and other discovery and platform related expenses, as well as increased personnel-related expenses, including incremental non-cash share-based compensation expense of $2.2 million associated with equity grants issued in the three months ended March 31, 2023, offset by incremental UK research and development tax credit reimbursements.<\/li>\n<li>General and administrative expenses were $14.5 million for the three months ended March 31, 2023, compared to $17.0 million for the three months ended March 31, 2022. The decrease of $2.5 million for the three months ended March 31, 2023 as compared to the same period in the prior year was primarily due to a decrease in non-cash share-based compensation expense compared to the previous year.<\/li>\n<li>Net loss was $39.1 million, or $(1.30) basic and diluted net loss per share, for the three months ended March 31, 2023, compared to net loss of $27.6 million, or $(0.93) basic and diluted net loss per share, for three months ended March 31, 2022.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle\u00ae) technology, today reported financial results for the first quarter ended March 31, 2023 and provided recent corporate updates. \u201cThe beginning of 2023 has been impactful for Bicycle and our platform,\u201d said Kevin [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":1332,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[6,29],"tags":[50],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Bicycle Therapeutics reports first quarter 2023 financial results and provides corporate update - Cambridge Innovation Capital<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cic.vc\/bicycle-therapeutics-reports-first-quarter-2023-financial-results-and-provides-corporate-update\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bicycle Therapeutics reports first quarter 2023 financial results and provides corporate update - Cambridge Innovation Capital\" \/>\n<meta property=\"og:description\" content=\"Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle\u00ae) technology, today reported financial results for the first quarter ended March 31, 2023 and provided recent corporate updates. \u201cThe beginning of 2023 has been impactful for Bicycle and our platform,\u201d said Kevin [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cic.vc\/bicycle-therapeutics-reports-first-quarter-2023-financial-results-and-provides-corporate-update\/\" \/>\n<meta property=\"og:site_name\" content=\"Cambridge Innovation Capital\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-05T13:07:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-04-16T12:12:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cic.vc\/wp-content\/uploads\/2023\/04\/Bicycle-Tx-bicycle-graphic.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1600\" \/>\n\t<meta property=\"og:image:height\" content=\"1200\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Victoria Woodward\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@cic_vc\" \/>\n<meta name=\"twitter:site\" content=\"@cic_vc\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Victoria Woodward\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.cic.vc\/bicycle-therapeutics-reports-first-quarter-2023-financial-results-and-provides-corporate-update\/\",\"url\":\"https:\/\/www.cic.vc\/bicycle-therapeutics-reports-first-quarter-2023-financial-results-and-provides-corporate-update\/\",\"name\":\"Bicycle Therapeutics reports first quarter 2023 financial results and provides corporate update - Cambridge Innovation Capital\",\"isPartOf\":{\"@id\":\"https:\/\/www.cic.vc\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.cic.vc\/bicycle-therapeutics-reports-first-quarter-2023-financial-results-and-provides-corporate-update\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.cic.vc\/bicycle-therapeutics-reports-first-quarter-2023-financial-results-and-provides-corporate-update\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cic.vc\/wp-content\/uploads\/2023\/04\/Bicycle-Tx-bicycle-graphic.png\",\"datePublished\":\"2023-04-05T13:07:04+00:00\",\"dateModified\":\"2024-04-16T12:12:00+00:00\",\"author\":{\"@id\":\"https:\/\/www.cic.vc\/#\/schema\/person\/d21ca8bed7490e644ef8d32b0e0fd95e\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.cic.vc\/bicycle-therapeutics-reports-first-quarter-2023-financial-results-and-provides-corporate-update\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.cic.vc\/bicycle-therapeutics-reports-first-quarter-2023-financial-results-and-provides-corporate-update\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/www.cic.vc\/bicycle-therapeutics-reports-first-quarter-2023-financial-results-and-provides-corporate-update\/#primaryimage\",\"url\":\"https:\/\/www.cic.vc\/wp-content\/uploads\/2023\/04\/Bicycle-Tx-bicycle-graphic.png\",\"contentUrl\":\"https:\/\/www.cic.vc\/wp-content\/uploads\/2023\/04\/Bicycle-Tx-bicycle-graphic.png\",\"width\":1600,\"height\":1200},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.cic.vc\/bicycle-therapeutics-reports-first-quarter-2023-financial-results-and-provides-corporate-update\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.cic.vc\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bicycle Therapeutics reports first quarter 2023 financial results and provides corporate update\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cic.vc\/#website\",\"url\":\"https:\/\/www.cic.vc\/\",\"name\":\"Cambridge Innovation Capital\",\"description\":\"We enable visionaries to build global, category-leading companies.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cic.vc\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.cic.vc\/#\/schema\/person\/d21ca8bed7490e644ef8d32b0e0fd95e\",\"name\":\"Victoria Woodward\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/www.cic.vc\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/af74430b55efa3224ea2e0bf88a42c72?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/af74430b55efa3224ea2e0bf88a42c72?s=96&d=mm&r=g\",\"caption\":\"Victoria Woodward\"},\"url\":\"https:\/\/www.cic.vc\/author\/victoria\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Bicycle Therapeutics reports first quarter 2023 financial results and provides corporate update - Cambridge Innovation Capital","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cic.vc\/bicycle-therapeutics-reports-first-quarter-2023-financial-results-and-provides-corporate-update\/","og_locale":"en_GB","og_type":"article","og_title":"Bicycle Therapeutics reports first quarter 2023 financial results and provides corporate update - Cambridge Innovation Capital","og_description":"Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle\u00ae) technology, today reported financial results for the first quarter ended March 31, 2023 and provided recent corporate updates. \u201cThe beginning of 2023 has been impactful for Bicycle and our platform,\u201d said Kevin [&hellip;]","og_url":"https:\/\/www.cic.vc\/bicycle-therapeutics-reports-first-quarter-2023-financial-results-and-provides-corporate-update\/","og_site_name":"Cambridge Innovation Capital","article_published_time":"2023-04-05T13:07:04+00:00","article_modified_time":"2024-04-16T12:12:00+00:00","og_image":[{"width":1600,"height":1200,"url":"https:\/\/www.cic.vc\/wp-content\/uploads\/2023\/04\/Bicycle-Tx-bicycle-graphic.png","type":"image\/png"}],"author":"Victoria Woodward","twitter_card":"summary_large_image","twitter_creator":"@cic_vc","twitter_site":"@cic_vc","twitter_misc":{"Written by":"Victoria Woodward","Estimated reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.cic.vc\/bicycle-therapeutics-reports-first-quarter-2023-financial-results-and-provides-corporate-update\/","url":"https:\/\/www.cic.vc\/bicycle-therapeutics-reports-first-quarter-2023-financial-results-and-provides-corporate-update\/","name":"Bicycle Therapeutics reports first quarter 2023 financial results and provides corporate update - Cambridge Innovation Capital","isPartOf":{"@id":"https:\/\/www.cic.vc\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cic.vc\/bicycle-therapeutics-reports-first-quarter-2023-financial-results-and-provides-corporate-update\/#primaryimage"},"image":{"@id":"https:\/\/www.cic.vc\/bicycle-therapeutics-reports-first-quarter-2023-financial-results-and-provides-corporate-update\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cic.vc\/wp-content\/uploads\/2023\/04\/Bicycle-Tx-bicycle-graphic.png","datePublished":"2023-04-05T13:07:04+00:00","dateModified":"2024-04-16T12:12:00+00:00","author":{"@id":"https:\/\/www.cic.vc\/#\/schema\/person\/d21ca8bed7490e644ef8d32b0e0fd95e"},"breadcrumb":{"@id":"https:\/\/www.cic.vc\/bicycle-therapeutics-reports-first-quarter-2023-financial-results-and-provides-corporate-update\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cic.vc\/bicycle-therapeutics-reports-first-quarter-2023-financial-results-and-provides-corporate-update\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.cic.vc\/bicycle-therapeutics-reports-first-quarter-2023-financial-results-and-provides-corporate-update\/#primaryimage","url":"https:\/\/www.cic.vc\/wp-content\/uploads\/2023\/04\/Bicycle-Tx-bicycle-graphic.png","contentUrl":"https:\/\/www.cic.vc\/wp-content\/uploads\/2023\/04\/Bicycle-Tx-bicycle-graphic.png","width":1600,"height":1200},{"@type":"BreadcrumbList","@id":"https:\/\/www.cic.vc\/bicycle-therapeutics-reports-first-quarter-2023-financial-results-and-provides-corporate-update\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.cic.vc\/"},{"@type":"ListItem","position":2,"name":"Bicycle Therapeutics reports first quarter 2023 financial results and provides corporate update"}]},{"@type":"WebSite","@id":"https:\/\/www.cic.vc\/#website","url":"https:\/\/www.cic.vc\/","name":"Cambridge Innovation Capital","description":"We enable visionaries to build global, category-leading companies.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cic.vc\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-GB"},{"@type":"Person","@id":"https:\/\/www.cic.vc\/#\/schema\/person\/d21ca8bed7490e644ef8d32b0e0fd95e","name":"Victoria Woodward","image":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.cic.vc\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/af74430b55efa3224ea2e0bf88a42c72?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/af74430b55efa3224ea2e0bf88a42c72?s=96&d=mm&r=g","caption":"Victoria Woodward"},"url":"https:\/\/www.cic.vc\/author\/victoria\/"}]}},"_links":{"self":[{"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/posts\/2071"}],"collection":[{"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/comments?post=2071"}],"version-history":[{"count":4,"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/posts\/2071\/revisions"}],"predecessor-version":[{"id":3003,"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/posts\/2071\/revisions\/3003"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/media\/1332"}],"wp:attachment":[{"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/media?parent=2071"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/categories?post=2071"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/tags?post=2071"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}